A Phase 2 interventional study of Association of darolutamide and EBRT and Association of ADT and EBRT in Prostate Cancer, sponsored by Institut Bergonié. Recruiting at 10 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Institut Bergonié · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Institut Bergonié — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Institut Bergonié.
Among the 10 studies in Prostatic Neoplasms by Institut Bergonié, this one is one of 2 that started in 2023, is one of 2 in phase 2, and was the 8th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 10 studies in Prostatic Neoplasms by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 720 across the 5 interventional studies, 50 across the 5 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Bergonié is the lead sponsor of 119 studies on the registry; 16 are open to participants now.
2 of the studies in Prostatic Neoplasms by Institut Bergonié that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06700057Institut BergoniéClinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer. | 2026-11-30 |
| NCT05346848Institut BergoniéRandomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Institut Bergonié, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
Multicentric randomized non-comparative, open-label, phase II trial, based on signle-stage design, to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
Patients satisfying eligibility criteria will be randomized according to 2 treatment modalities
Two patients randomized in arm A for one patient randomized in arm B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unfavorable intermediate risk prostate cancer diagnosis defined by the NCCN Guidelines.
One of the following criteria is sufficient to define an unfavorable intermediate risk prostate cancer:
If these criteria are not being identified, two or three of the following criteria are necessary to define unfavorable intermediate risk prostate cancer:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy
Drug: Association of darolutamide and EBRT
Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy
Drug: Association of ADT and EBRT
Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1. \- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules: * 78 Gy with classical 2 Gy/fractions, 5 days/7 * Or 60 Gy with 3 Gy/fractions, 5 days/7 * Use of IMRT and IGRT is mandatory * Clinical Target Volume Definition according to GETUG Guidelines * Organ at risk dose constraints according to RECORAD
Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on: * Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months, * Either LH-RH antagonist given monthly for 6 months External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions: * 78 Gy with classical 2 Gy/fractions, 5 days/7 * Or 60 Gy with 3 Gy/fractions, 5 days/7 * Use of IMRT and IGRT is mandatory * Clinical Target Volume Definition according to GETUG Guidelines * Organ at risk dose constraints according to RECORAD
Assessment of efficacy in terms of 6-month biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 6 months after randomization
Assessment of efficacy in terms of biological response at the end of darolutamide or ADT
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: An expected average of 6 months
2-month biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 2 months after randomization
3-month biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 3 months after the end of radiotherapy
6-month biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 6 months after the end of radiotherapy
9-month biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 9 months after the end of radiotherapy
2-year biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 2 years after randomization
3-year biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 3 years after randomization
5-year biological response
Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria
Time frame: 5 years after randomization
2-year biochemical progression-free survival (bPFS)
Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.
Time frame: 2 years
3-year biochemical progression-free survival (bPFS)
Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.
Time frame: 3 years
5-year biochemical progression-free survival (bPFS)
Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.
Time frame: 5 years
2-year metastasis free survival (MFS)
Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)
Time frame: 2 years
3-year metastasis free survival (MFS)
Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)
Time frame: 3 years
5-year metastasis free survival (MFS)
Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)
Time frame: 5 years
2-year disease free survival (DFS)
Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)
Time frame: 2 years
3-year disease free survival (DFS)
Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)
Time frame: 3 years
5-year disease free survival (DFS)
Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)
Time frame: 5 years
2-year prostate cancer-specific survival (PCSS)
Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death
Time frame: 2 years
3-year prostate cancer-specific survival (PCSS)
Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death
Time frame: 3 years
5-year prostate cancer-specific survival (PCSS)
Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death
Time frame: 5 years
2-year overall survival (OS)
Overall survival is defined as the delay between the date of randomization and the date of death (all cause).
Time frame: 2 years
3-year overall survival (OS)
Overall survival is defined as the delay between the date of randomization and the date of death (all cause).
Time frame: 3 years
5-year overall survival (OS)
Overall survival is defined as the delay between the date of randomization and the date of death (all cause).
Time frame: 5 years
Time to testosterone recovery
Time to testosterone recovery defined as the time from randomization to the time when serum of total testosterone level increases to above the lower limit of the normal range.
Time frame: An expected average of 6 months
Acute safety profile independently for each treatment strategy
Toxicity graded using the Common Terminology Criteria for Adverse Events version 5
Time frame: 3 months
Late 2-year safety profile independently for each treatment strategy
Toxicity graded using the Common Terminology Criteria for Adverse Events version 5
Time frame: 2 years
Late 3-year safety profile independently for each treatment strategy
Toxicity graded using the Common Terminology Criteria for Adverse Events version 5
Time frame: 3 years
Late 5-year safety profile independently for each treatment strategy
Toxicity graded using the Common Terminology Criteria for Adverse Events version 5
Time frame: 5 years
Assessment of quality of life
Quality of life will be assessed as per the EORTC QLQ-C30 questionnaire and prostate cancer module PR-25
Time frame: Throughout the follow-up period, an expected average of 5 years
Assessment of erectile dysfunction
Erectile dysfunction will be assessed as per IIEF5
Time frame: Throughout the follow-up period, an expected average of 5 years
Assessment of symptoms of benign prostatic hyperplasia
Symptoms of benign prostatic hyperplasia will be assessed as per IPSS
Time frame: Throughout the follow-up period, an expected average of 5 years
Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 46 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.